Adam Lazorchak

Adam Lazorchak has over 14 years of work experience in the biopharmaceutical industry. Adam began their career in 2007 as a Postdoc Fellow and Associate Research Scientist at Yale University School of Medicine. During their time there, they conducted research on how intracellular signaling pathways influence the immune system and developed a novel method to treat blood cancer.

In 2013, they joined ImStem Biotechnology Inc. as a Senior Scientist and Preclinical Director. At ImStem, they led the preclinical development of a human stem cell derived immunotherapy for the treatment of multiple sclerosis.

In 2015, Adam moved to Curis where they held two roles: Associate Director, Translational Sciences, Immunology and Senior Scientist & Immunology Preclinical Lead. In this role, they were responsible for leading a team tasked with biomarker discovery, mechanism-of-action and non-clinical research in support of Curis's small molecule immune-oncology programs.

In 2018, Adam joined EMD Serono, Inc. as a Group Leader and Principal Scientist (Oncology and Immuno-Oncology).

Most recently, in 2021, they joined Be Biopharma as the Director, Translational Biology. At Be Biopharma, Adam is building novel gene edited B cell medicines and leveraging a broad range of approaches including cellular, biochemical and in vivo models to bring their B cell medicines to patients.

Adam Lazorchak obtained a Bachelor of Science (BS) in Biotechnology from Rutgers University between 1996 and 2000. Adam then went on to pursue a Doctor of Philosophy (Ph.D.) in Immunology from Duke University, which they completed in 2006.